1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.